U of T’s Deep Genomics secures $40 million in financing for AI drug development platform: Betakit

portrait of Brendan Frey seated at a desk
Brendan Frey is the CEO of Deep Genomics and a professor in U of T's Faculty of Applied Science & Engineering (photo by Johnny Guatto)

Deep Genomics, an artificial intelligence-powered drug discovery start-up co-founded by the University of Toronto’s Brendan Frey, recently raised $40 million in Series B funding, Betakit reports.

The latest round, led by Future Ventures and including investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures, brings the startup’s total funding to date to $61 million.

Betakit notes that Deep Genomics in September “identified a new treatment target and corresponding drug candidate for Wilson disease,” a rare genetic disorder that causes an accumulation of copper in vital organs, which can be fatal if left untreated.

The capital will help Deep Genomics, which announced the financing last week, bring its Wilson disease program to the clinic, said Frey, a founding member of the Vector Institute for Artificial Intelligence and a professor in the department of electrical and computer engineering in the Faculty of Applied Science & Engineering. 

Read the story at Betakit